Medtech Start-Ups: Raising Capital & Gaining Attention from Strategics

Posted by Life Science Intelligence on Jun 19, 2020 8:39:03 AM
Find me on:

LSI's Medtech Start-Up Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.  

Digital health startup Cue Health raises $100M in Series C round
Cue has developed a diagnostic platform that provides patients and healthcare providers with convenient access to health information through smart devices. With the latest round of fundraising, the company has raised $181M. Digital health continues to surge due to the interest of traditional medtech companies and consumer technology companies such as Microsoft, Apple, and Samsung.

Start a Free Trial to Medtech Start-Up Today

A self-expanding, high performance heart assist device is being developed by NovaPump
The PERKAT device is a minimally invasive heart assist device that can be deployed within a few minutes via a percutaneous approach. NovaPump recently completed a Series A funding round lead by High-Tech Grunderfonds, a German venture capital group. The minimally invasive cardiovascular devices market is one of the largest medtech markets, with major competitors such as Abbott, Boston Scientific, Edwards, and Medtronic.  

MedtechUnicorn_June17Profiles_LinkedIN-1

HistoSonics is developing an ultrasonic ablation system to destroy tissue at cellular and sub-cellular levels
In June the company completed a Series C round for $40M. To-date the company has raised $127M. Key strategics in this market include: Urologix, Boston Scientific, and Medtronic, among others.

MetaOptima Technology is developing advanced digital health solutions for the dermatology market
The company is focused on developing skin imaging and analytics platforms to detect skin cancer early. To-date the company has raised $6.5M. Key strategics in this market include Roche Diagnostics, Thermo Fisher, and SkinVision.

Clinical-stage cell therapeutics company Celularity is seeking to improve human longevity through targeted and functional repair of tissues
Celularity is developing its IMPACT (Immuno-Modulatory Placenta-derived Allogenic Cell Therapy) platform. The company is developing multiple product candidates for age-related diseases, inflammatory conditions, and oncology. To-date the company has raised $290M.

HMCARE prepares to test the prototype of its HelloMask – a fully transparent surgical mask
On June 10, 2020, the company completed its first round of fundraising – a Seed round for $1.1M in capital. As the global pandemic due to COVID-19 persists, many startups have emerged with novel respiratory solutions, such as CorVent Medical, Breathio, and The Ventilator Project.

A novel, 3-dimensional modeling platform for oncology is in development at CuResponse
CuResponse’s platform is seeking to personalize cancer treatment by providing a 3D tissue culture system for modeling cancer growth and tissue response to pharmaceuticals. The company raised $6M in a Series A round from investors at NCL Technology Ventures and aMoon Fund. The technology is a potential for developers of pharmaceuticals for oncology, such as AstraZeneca, BMS, and Lilly, to identify patients that will respond well to their therapies.

Track the companies driving innovation in medtech by starting a trial to LSI's Medtech Start-Up Tracker.

Stay connected with our latest posts:

About the Author

Life Science Intelligence (LSI) helps medtech executives make better strategic decisions by delivering unique market data and business insights. For over 13 years LSI has been working with industry giants – Johnson & Johnson, Medtronic, Abbott, Stryker, Cardinal, Boston Scientific, and Becton Dickinson, among others. LSI products are also leveraged by the most successful start-ups, innovators, investors, and service companies that compete in medtech. LSI is the organizer of The Emerging Medtech Summit held annually in Southern California.

Contact LSI here, via phone 714 847 3540, or email info@lsintel.com